Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who were assessed before surgery as having early-stage ovarian cancer that starts in the surface cells of the ovary (called epithelial ovarian cancer)
- People who had surgery between January 2014 and December 2023
- People who had open surgery or minimally invasive surgery (such as laparoscopic or robotic-assisted surgery) to stage or re-stage their cancer
- People whose final pathology report (lab results from tissue removed during surgery) confirmed a diagnosis of epithelial ovarian cancer
Who may not be able to join:
- People who did not have a complete surgical staging procedure
- People who received chemotherapy before their surgery (called neoadjuvant chemotherapy)
- People who had a second, separate invasive cancer at the same time as their ovarian cancer
- People for whom informed consent was not obtained
- People rated as ASA class 4 or 5, which generally refers to people with very severe or life-threatening health conditions affecting their overall fitness for surgery (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +39 3335384990
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To assess the number of patients with 30-day post-operative complication in the two groups (minimally invasive surgery and open surgery); To assess the number of patients with 30-day post-operative hospital readmission in the two groups (minimally invasive surgery and open surgery); To assess the number of patients with 30-day post-operative reoperation in the two groups (minimally invasive surgery and open surgery); To assess the rate of upstaging in the two groups (minimally invasive surgery and open surgery); To assess the rate of conversion in the minimally invasive surgery group
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.